Related Experiment Video
Updated: Jun 9, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells
Omar Flores1, Kerry L Burnstein
1Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, 1600 NW 10th Avenue, R-189, Room 6155 Rosenstiel Building, Miami, Florida 33136, USA.
Abstract:
1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] inhibits proliferation of normal and malignant prostate epithelial cells at least in part through inhibition of G1 to S phase cell cycle progression. The mechanisms of the antiproliferative effects of 1,25-(OH)2D3 have yet to be fully elucidated but are known to require the vitamin D receptor. We previously developed a 1,25-(OH)2D3-resistant derivative of the human prostate cancer cell line, LNCaP, which retains active vitamin D receptors but is not growth inhibited by 1,25-(OH)2D3. Gene expression profiling revealed two novel 1,25-(OH)2D3-inducible genes, growth arrest and DNA damage-inducible gene gamma (GADD45γ) and mitogen induced gene 6 (MIG6), in LNCaP but not in 1,25-(OH)2D3-resistant cells. GADD45γ up-regulation was associated with growth inhibition by 1,25-(OH)2D3 in human prostate cancer cells. Ectopic expression of GADD45γ in either LNCaP or ALVA31 cells resulted in G1 accumulation and inhibition of proliferation equal to or greater than that caused by 1,25-(OH)2D3 treatment. In contrast, ectopic expression of MIG6 had only minimal effects on cell cycle distribution and proliferation. Whereas GADD45γ has been shown to be induced by androgens in prostate cancer cells, up-regulation of GADD45γ by 1,25-(OH)2D3 was not dependent on androgen receptor signaling, further refuting a requirement for androgens/androgen receptor in vitamin D-mediated growth inhibition. These data introduce two novel 1,25-(OH)2D3-regulated genes and establish GADD45γ as a growth-inhibitory protein in prostate cancer. Furthermore, the induction of GADD45γ gene expression by 1,25-(OH)2D3 may mark therapeutic response in prostate cancer.
Insights
1,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by regulating GADD45γ. This vitamin D metabolite
Area of Science:
- Molecular Biology
- Oncology
- Cell Biology
Background:
- 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] is known to inhibit prostate cancer cell proliferation by affecting cell cycle progression.
- The precise mechanisms underlying 1,25-(OH)2D3's antiproliferative effects, while requiring the vitamin D receptor, are not fully understood.
- A 1,25-(OH)2D3-resistant prostate cancer cell line (LNCaP) was developed, retaining vitamin D receptors but lacking growth inhibition by 1,25-(OH)2D3.
Purpose of the Study:
- To elucidate the molecular mechanisms of 1,25-(OH)2D3's antiproliferative effects in prostate cancer cells.
- To identify novel genes regulated by 1,25-(OH)2D3 in prostate cancer.
- To establish the role of identified genes, specifically GADD45γ and MIG6, in vitamin D-mediated growth inhibition.
Main Methods:
- Gene expression profiling was performed on LNCaP and 1,25-(OH)2D3-resistant cells to identify differentially expressed genes.
- The function of identified genes (GADD45γ and MIG6) was investigated through ectopic expression in prostate cancer cell lines (LNCaP, ALVA31).
- Cell cycle progression and proliferation were analyzed following gene manipulation and 1,25-(OH)2D3 treatment.
Main Results:
- Gene expression profiling identified two novel 1,25-(OH)2D3-inducible genes: GADD45γ and MIG6, in responsive LNCaP cells but not in resistant cells.
- GADD45γ up-regulation correlated with 1,25-(OH)2D3-induced growth inhibition; ectopic GADD45γ expression caused G1 cell cycle arrest and proliferation inhibition.
- 1,25-(OH)2D3-induced GADD45γ expression was independent of androgen receptor signaling, suggesting a distinct pathway for vitamin D-mediated growth inhibition.
Conclusions:
- GADD45γ is identified as a novel 1,25-(OH)2D3-regulated gene that mediates growth inhibition in prostate cancer cells.
- Ectopic expression of GADD45γ effectively inhibits prostate cancer cell proliferation and induces G1 cell cycle arrest, mimicking 1,25-(OH)2D3 effects.
- The induction of GADD45γ by 1,25-(OH)2D3 presents a potential biomarker for therapeutic response in prostate cancer treatment.
Related Concept Videos
Activation and Inactivation of G Proteins
TGF - β Signaling Pathway
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Negative Regulator Molecules

